

Bruce E Sands

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/364883/bruce-e-sands-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

361
papers

32,423
citations

78
h-index

178
g-index

431
ext. papers

38,870
ext. citations

7
avg, IF

6.99
L-index

#	Paper	IF	Citations
361	Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.. <i>Gastroenterology</i> , 2022 ,	13.3	12
360	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity.. <i>Nature Medicine</i> , 2022 ,	50.5	2
359	Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.. <i>BMC Gastroenterology</i> , 2022 , 22, 71	3	
358	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).. <i>BMJ Open</i> , 2022 , 12, e057656	3	1
357	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients with Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.. <i>Gastroenterology</i> , 2022 ,	13.3	1
356	Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 281-290	6.1	3
355	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2021 ,	13.3	7
354	Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, S17-S24	4.5	1
353	P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. <i>American Journal of Gastroenterology</i> , 2021 , 116, S8	0.7	0
352	S777 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials. <i>American Journal of Gastroenterology</i> , 2021 , 116, S360-S360	0.7	0
351	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1442-1453	6.1	1
350	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1576-1584	4.5	2
349	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2541-2550.e1	6.9	7
348	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. <i>Gut</i> , 2021 , 70, 418-426	19.2	8
347	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 994-1007	4.5	17
346	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2021 ,	4.5	1
345	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4

344	Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home. <i>Journal of Pharmacy Practice</i> , 2021 , 8971900211000682	1.3	1
343	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021 , 160, 1452-1460.e21	13.3	15
342	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021 , 160, 1570-1583	13.3	191
341	Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. <i>Crohn's & Colitis</i> 360 , 2021 , 3,	1.4	1
340	Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. <i>RMD Open</i> , 2021 , 7,	5.9	9
339	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021 , 160, 2291-2302	13.3	10
338	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1836-1844	4	4
337	Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. <i>Gastroenterology</i> , 2021 , 160, 287-301.e20	13.3	50
336	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021 , 160, 1131-1139	13.3	36
335	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 797-808	4.5	4
334	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 950-959	1.5	8
333	New Therapeutics for Ulcerative Colitis. <i>Annual Review of Medicine</i> , 2021 , 72, 199-213	17.4	7
332	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	16
331	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. <i>Journal of Medical Internet Research</i> , 2021 , 23, e31295	7.6	3
330	Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension. <i>Gastroenterology</i> , 2021 , 161, 1953-1968.e15	13.3	2
329	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , 2021 , 161, 1156-1167.e3	13.3	2
328	Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 599-632	7.9	2
327	Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. <i>Cell Host and Microbe</i> , 2021 , 29, 83-93.e3	23.4	18

326	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 997-998	6.1	1
325	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1209-1210	6.1	1
324	The day after COVID-19 in IBD: how to go back to 'normal'. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 441-443	24.2	12
323	Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. <i>Clinical and Experimental Gastroenterology</i> , 2020 , 13, 211-220	3.1	1
322	Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic study. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 795-799	2.4	3
321	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2952-2961	6.0	21
320	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1658-1675	6.1	15
319	S0664 Disease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis. <i>American Journal of Gastroenterology</i> , 2020 , 115, S332-S333	0.7	
318	S0703 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials. <i>American Journal of Gastroenterology</i> , 2020 , 115, S353-S354	0.7	3
317	S0887 Fecal Calprotectin as a Surrogate Marker of Clinical Remission, Clinical Response, Endoscopic Improvement, and Histo-Endoscopic Mucosal Healing: UNIFI Induction Study. <i>American Journal of Gastroenterology</i> , 2020 , 115, S457-S458	0.7	
316	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 271-280	6.1	27
315	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. <i>American Journal of Gastroenterology</i> , 2020 , 115, 738-745	0.7	32
314	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2244-2255.e9	6.9	30
313	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 553-564	6.1	13
312	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	10
311	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 669-681	6.1	21
310	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	5
309	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1353-1365	6.1	34

308	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020 , 159, 2052-2064	13.3	17
307	Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity. <i>Gut</i> , 2020 , 69, 401-402	19.2	6
306	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 23-32	1.5	75
305	Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1050-1058	4.5	7
304	Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 123-132.e3	6.9	46
303	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019 , 157, 1032-1043.e1	13.3	31
302	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1215-1226	59.2	240
301	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019 , 381, 1201-1214	59.2	354
300	Novel Non-biologic Targets for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2019 , 21, 22	5	8
299	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1854-1861	4.5	9
298	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 969-979	4.5	21
297	Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. <i>BMC Gastroenterology</i> , 2019 , 19, 47	3	23
296	Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1541-1550	6.9	116
295	A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1262-1270	4.5	8
294	Gut microbiota density influences host physiology and is shaped by host and microbial factors. <i>ELife</i> , 2019 , 8,	8.9	72
293	Reply to Letter to the Editor of Dr. Lai and Colleagues. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e166	4.5	
292	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1068-1076	6.1	92
291	Efficient augmentation and relaxation learning for individualized treatment rules using observational data. <i>Journal of Machine Learning Research</i> , 2019 , 20,	28.6	5

290	Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond. <i>Gastroenterology and Hepatology</i> , 2019 , 15, 682-684	0.7	
289	Response to Chamberlin and Borody. <i>American Journal of Gastroenterology</i> , 2019 , 114, 171-174	0.7	
288	671 An Update on the Analysis of Non-Melanoma Skin Cancer in the Tofacitinib Ulcerative Colitis Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, S395-S395	0.7	0
287	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S612-S613	1.5	19
286	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 1217-1226	1.5	4
285	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2497-2505.e1	6.9	25
284	757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY. <i>American Journal of Gastroenterology</i> , 2019 , 114, S442-S442	0.7	
283	716 Early Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. <i>American Journal of Gastroenterology</i> , 2019 , 114, S421-S421	0.7	
282	Response to Ribaldone. <i>American Journal of Gastroenterology</i> , 2019 , 114, 826-827	0.7	
281	Response to Chapman and Jones. <i>American Journal of Gastroenterology</i> , 2019 , 114, 828	0.7	
280	644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program. <i>American Journal of Gastroenterology</i> , 2019 , 114, S377-S377	0.7	
279	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1533-1540.e2	6.9	40
278	Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and ROR γ Regulatory T Cells and Exacerbate Colitis in Mice. <i>Immunity</i> , 2019 , 50, 212-224.e4	32.3	189
277	Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1375-1382	4.5	9
276	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1673-1679.e1	6.9	13
275	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 803-810	4.5	17
274	Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 651-659	4.5	23
273	What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 618-620	6.9	1

272	When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 621-623	6.9	6
271	Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 155-160	2.2	4
270	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 408-418	1.5	66
269	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 883-895	1.5	10
268	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 76-87	13.3	29
267	14 POST-HOC ANALYSIS OF TOFACITINIB CROHN'S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. <i>Gastroenterology</i> , 2018 , 154, S81	13.3	9
266	ACG Clinical Guideline: Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2018 , 113, 481-517	0.7	518
265	Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. <i>Human Pathology</i> , 2018 , 79, 42-49	3.7	12
264	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018 , 67, 244-254	19.2	73
263	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 145-156	1.5	55
262	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2018 , 154, 61-64.e6	13.3	46
261	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 687-695.e10	13.3	60
260	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1158-1169	1.5	70
259	There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 333-338	3	15
258	Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. <i>Gastroenterology</i> , 2018 , 155, 1079-1089.e3	13.3	93
257	Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2018 , 155, 1098-1108.e9	13.3	43
256	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2461-2467	4.5	33
255	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 65-77	6.1	80

254	Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1345	0.7	87
253	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017 , 66, 839-851	19.2	478
252	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017 , 66, 1049-1059	19.2	203
251	Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. <i>Digestive Diseases</i> , 2017 , 35, 13-20	3.2	13
250	Optimal Management of Fistulizing Crohn's Disease 2017 , 381-386		
249	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. <i>Gastroenterology</i> , 2017 , 152, S199	13.3	2
248	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1723-1736	59.2	771
247	Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease. <i>Gastroenterology</i> , 2017 , 152, S185	13.3	42
246	Long-Term Efficacy and Safety of Ustekinumab for Crohn's Disease: Results From Im-Uniti Long-Term Extension Through two Years. <i>Gastroenterology</i> , 2017 , 152, S585	13.3	2
245	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 921-929	1.5	99
244	Eldelumab [anti-interferon- γ inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 811-819	1.5	19
243	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017 , 153, 77-86.e6	13.3	162
242	Maintenance of Quality of Life Improvement in a Phase 3 Study of Tofacitinib for Patients with Moderately to Severely Active Ulcerative Colitis. <i>Gastroenterology</i> , 2017 , 152, S601-S602	13.3	9
241	Exposure to Biologic Therapy and Childhood Development among Offspring of Women with Inflammatory Bowel Disease: Results from the Piano Registry. <i>Gastroenterology</i> , 2017 , 152, S85-S86	13.3	9
240	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. <i>Gastroenterology</i> , 2017 , 152, S371	13.3	11
239	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017 , 152, S602	13.3	7
238	Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium. <i>Gastroenterology</i> , 2017 , 152, S779	13.3	2
237	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 97-106	4.5	110

236	Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 347-356	4.5	30
235	Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 14-22	4.5	17
234	Dietary behaviors in newly diagnosed youth with inflammatory bowel disease. <i>Children's Health Care</i> , 2017 , 46, 408-420	0.9	6
233	Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2017 , 112, S329-S330	0.7	4
232	Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award. <i>American Journal of Gastroenterology</i> , 2017 , 112, S400-S401	0.7	
231	Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, S329-S330	0.7	
230	Integrated Safety Analyses of Tofacitinib in Ulcerative Colitis Clinical Trials. <i>American Journal of Gastroenterology</i> , 2017 , 112, S403-S404	0.7	1
229	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 412-424	1.5	112
228	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 400-411	1.5	109
227	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 1946-1960	59.2	896
226	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1147-55	0.7	198
225	Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. <i>Gastroenterology</i> , 2016 , 150, S974	13.3	2
224	855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2016 , 150, S182-S183	13.3	9
223	Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. <i>Gastroenterology</i> , 2016 , 150, S392-S393	13.3	2
222	Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials. <i>Gastroenterology</i> , 2016 , 150, S1004	13.3	9
221	P-016 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S14	4.5	
220	P-063 Psychosocial Burden Among Patients with IBD: Prospectively Collected Data from 2 Academic Institutions. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S29	4.5	
219	Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1635-40	4	7

218	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1245-1255.e8	6.9	158
217	Risk factors for radiation exposure in newly diagnosed IBD patients. <i>Abdominal Radiology</i> , 2016 , 41, 1363-9		9
216	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 418-28	1.5	38
215	Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2016 , 111, S261	0.7	3
214	Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2016 , 111, S319-S320	0.7	2
213	Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. <i>Journal of Medical Internet Research</i> , 2016 , 18, e124	7.6	3
212	Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 607-14	4.5	20
211	Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1456-61	4.5	18
210	P-017 YI Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S14	4.5	
209	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. <i>Gastroenterology</i> , 2016 , 151, 710-723.e2	13.3	40
208	Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 317-33	6.1	180
207	Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016 , 3, 38-44		9
206	Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2016 , 31, 973-982	3	17
205	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Severe Crohn's Disease Refractory to Anti-TNF. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S1	4.5	39
204	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1361-2	6.9	
203	437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry. <i>Gastroenterology</i> , 2016 , 150, S91-S92	13.3	28
202	Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1347-8	6.1	
201	Biomarkers of Inflammation in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015 , 149, 1275-1285.e2	13.3	183

200	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 607-16	1.5	40
199	Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1197-200	6.9	38
198	Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 842-6	6.9	7
197	Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 1103-9	2.4	22
196	Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 564-9	4.5	9
195	Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. <i>Gastroenterology</i> , 2015 , 149, 1131-3	13.3	8
194	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. <i>Gastroenterology</i> , 2015 , 148, 37-51.e1	13.3	162
193	Serum Proteome Profiles in Strictureing Crohn's Disease: A Pilot Study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1935-41	4.5	20
192	Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1809-16	4.5	44
191	Body image dissatisfaction in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 345-52	4.5	22
190	The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. <i>Gastroenterology</i> , 2015 , 148, 462-7	13.3	36
189	High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 266-75	1.5	31
188	Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2015 , 4, e23	2	40
187	Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1083-4	0.7	3
186	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 845-51	1.5	36
185	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. <i>Gastroenterology</i> , 2014 , 147, 618-627.e3	13.3	468
184	Anti-TNF therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1862-9	4.5	55
183	Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 398-415	4.5	25

- 182 Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn's Disease. *American Journal of Gastroenterology*, **2014**, 109, S478-S479 0.7 3
- 181 New drugs on the horizon for IBD. *Digestive Diseases*, **2014**, 32 Suppl 1, 74-81 3.2 17
- 180 Ischemic Disease of the Small and Large Bowel **2014**, 422-434
- 179 Approach to Dysphagia **2014**, 1-12
- 178 Barrett's Esophagus **2014**, 111-119
- 177 Approach to the Pregnant Patient with GI Disorders **2014**, 87-98
- 176 Approach to Nutrition Assessment **2014**, 78-86
- 175 Approach to Gastrointestinal Bleeding **2014**, 68-77
- 174 Approach to Fecal Incontinence **2014**, 56-67
- 173 Approach to Constipation **2014**, 45-55
- 172 Approach to Diarrhea **2014**, 31-44
- 171 Approach to Abdominal Pain **2014**, 21-30
- 170 Approach to Nausea and Vomiting **2014**, 13-20
- 169 Complications of Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis **2014**, 390-397
- 168 Vascular Lesions of the GI Tract **2014**, 347-357
- 167 GI Complications of Transplant **2014**, 336-346
- 166 Disorders of the Biliary Tract **2014**, 323-335
- 165 Pancreatic Cysts and Tumors **2014**, 304-322

164 Pancreatitis (Acute, Chronic, Autoimmune) **2014**, 292-303

163 Neuroendocrine Tumors **2014**, 279-291

162 GI Stromal Tumors **2014**, 270-278

161 Immunodeficiency and the GI Tract **2014**, 260-269

160 Infectious Enteritis and Colitis; Bacterial Food Poisoning; Intestinal Protozoa and Helminthic Infestations **2014**, 250-259

o

159 Bacterial Overgrowth **2014**, 233-237

158 Short Bowel Syndrome and Malnutrition **2014**, 222-232

157 Tumors of the Foregut **2014**, 213-221

156 GI Complications of Obesity Surgery **2014**, 203-212

155 Gastroparesis **2014**, 193-202

154 Esophageal Motility Disorders **2014**, 131-142

153 Esophageal Disorders Related to Medication, Trauma, and Infection **2014**, 143-155

152 Management of Foreign Bodies of the GI Tract **2014**, 156-159

151 Functional Dyspepsia **2014**, 160-169

150 Helicobacter pylori Treatment and Eradication **2014**, 180-192

149 Radiation Enterocolitis **2014**, 398-410

148 Clostridium difficile **2014**, 411-421

147 Diverticular Diseases of the Colon **2014**, 435-442

146	Adenocarcinoma of the Large Bowel and Hereditary Colon Cancer Syndromes 2014 , 443-454		
145	Surveillance for Dysplasia in Inflammatory Bowel Disease 2014 , 467-476		
144	Diseases of the Anus and Rectum 2014 , 477-486		
143	Complications of GI Endoscopy 2014 , 487-498		
142	Colonoscopic Polypectomy 2014 , 455-466		
141	Mark Warren Babyatsky, MD (June 29, 1959-August 25, 2014). <i>Gastroenterology</i> , 2014 , 147, 1189-90	13.3	1
140	Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 811-22	6.1	78
139	Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 534-40	4.5	26
138	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , 2013 , 369, 711-21	59.2	1328
137	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2	1465
136	Reliability and initial validation of the ulcerative colitis endoscopic index of severity. <i>Gastroenterology</i> , 2013 , 145, 987-95	13.3	254
135	Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e635-40	1.5	30
134	The Incidence of Influenza and Influenza-related Complications in Inflammatory Bowel Disease Patients across the United States. <i>American Journal of Gastroenterology</i> , 2013 , 108, S554	0.7	2
133	Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohn's Disease Treated with Vedolizumab. <i>American Journal of Gastroenterology</i> , 2013 , 108, S503	0.7	5
132	A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. <i>Gut</i> , 2013 , 62, 1288-94	19.2	38
131	A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. <i>Journal of Clinical Gastroenterology</i> , 2013 , 47, e1-6	3	59
130	Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1073-9	4.5	40
129	Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 644-9	4.5	25

128	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2013 , 108, S502-S503	0.7	12
127	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. <i>Genome Biology</i> , 2012 , 13, R79	18.3	1668
126	Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 46-51	6.9	37
125	Ustekinumab induction and maintenance therapy in refractory Crohn's disease. <i>New England Journal of Medicine</i> , 2012 , 367, 1519-28	59.2	813
124	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012 , 61, 1693-700	19.2	995
123	Abatacept for Crohn's disease and ulcerative colitis. <i>Gastroenterology</i> , 2012 , 143, 62-69.e4	13.3	105
122	Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. <i>Gastroenterology</i> , 2012 , 143, 356-64.e1	13.3	30
121	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2012 , 107, S609-S610	0.7	4
120	Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 201-11	4.5	146
119	Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2056-62	4.5	27
118	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012 , 61, 535-42	19.2	328
117	Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. <i>Gut</i> , 2012 , 61, 385-91	19.2	82
116	A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1051-63	0.7	153
115	P-26 Vedolizumab Induction Therapy for Patients With Crohn's Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S24-S25	4.5	3
114	Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S25	4.5	2
113	The risks and benefits of early immunosuppression and biological therapy. <i>Digestive Diseases</i> , 2012 , 30 Suppl 3, 100-6	3.2	19
112	Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S1-S2	4.5	8
111	Low Rate of Clostridium Difficile Infection Testing in Patients With Newly Diagnosed Inflammatory Bowel Disease and Diarrhea. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S42-S43	4.5	

110	Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. <i>Medicine and Health, Rhode Island</i> , 2012 , 95, 4-8		3
109	Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. <i>Gastroenterology</i> , 2011 , 141, 1194-201	13.3	646
108	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. <i>American Journal of Gastroenterology</i> , 2011 , 106, 199-212; quiz 213	0.7	291
107	Nutrition and dietary behaviors in pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S32	4.5	
106	Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?. <i>Surgery</i> , 2011 , 149, 72-8	3.6	37
105	Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 99-104	4.5	30
104	Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 30-8	4.5	62
103	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1415-22	4.5	395
102	IBD: Medical Management 2011 , 463-478		
101	Functionally defective germline variants of sialic acid acetyltransferase in autoimmunity. <i>Nature</i> , 2010 , 466, 243-7	50.4	129
100	Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. <i>Journal of Managed Care Pharmacy</i> , 2010 , 16, 616-28		49
99	The inflammatory bowel diseases and ambient air pollution: a novel association. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2412-9	0.7	155
98	LRRK2 is involved in the IFN-gamma response and host response to pathogens. <i>Journal of Immunology</i> , 2010 , 185, 5577-85	5.3	278
97	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 233-42	4.5	152
96	Babesiosis in a patient on infliximab for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1269-70	4.5	4
95	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1209-18	4.5	62
94	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1658-62	4.5	42
93	Efficacy of methotrexate in ulcerative colitis: failure or promise. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1421-30	4.5	26

92	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. <i>Inflammatory Bowel Diseases</i> , 2010 , 16 Suppl 1, S1-11	4.5	14
91	The placebo response rate in irritable bowel syndrome and inflammatory bowel disease. <i>Digestive Diseases</i> , 2009 , 27 Suppl 1, 68-75	3.2	19
90	Response to Letter by Field et al, Influenza Vaccinations: Should They Really be Encouraged for IBD Patients Being Treated with Immunosuppressives? <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 651-652	4.5	1
89	Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 599-607	4.5	16
88	Are adult patients more tolerant of treatment risks than parents of juvenile patients?. <i>Risk Analysis</i> , 2009 , 29, 121-36	3.9	35
87	389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis. <i>Gastroenterology</i> , 2009 , 136, A-65	13.3	2
86	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. <i>Gastroenterology</i> , 2009 , 137, 1250-60; quiz 1520	13.3	377
85	Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 874-81	6.9	395
84	Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009 , 48, 61-5	2.8	118
83	Transition to Adult Care. <i>Pediatric and Adolescent Medicine</i> , 2009 , 191-198	0.4	
82	Epidemiology of inflammatory bowel disease and overview of pathogenesis. <i>Medicine and Health, Rhode Island</i> , 2009 , 92, 73-7		8
81	OSCCAR: Ocean State Crohn's and Colitis Area Registry. <i>Medicine and Health, Rhode Island</i> , 2009 , 92, 82-5, 88		9
80	Infliximab vs. Adalimumab for Crohn's disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1266-1267	6.1	1
79	Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. <i>Gastroenterology</i> , 2008 , 134, 688-95	13.3	173
78	Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. <i>Gastroenterology</i> , 2008 , 134, 680-7	13.3	218
77	A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. <i>Gastroenterology</i> , 2008 , 135, 400-9	13.3	167
76	The risk of developing Crohn's disease after an appendectomy: a meta-analysis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2925-31	0.7	98
75	Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. <i>American Journal of Gastroenterology</i> , 2008 , 103, 3123-31	0.7	33

74	Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 1730-6; discussion 1736-7	3.3	187
73	Fulminant colitis. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 2157-9	3.3	9
72	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 1-6	4.5	47
71	Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. <i>Gastroenterology</i> , 2007 , 133, 769-79	13.3	142
70	American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. <i>Gastroenterology</i> , 2007 , 133, 312-39	13.3	167
69	Crohn's Disease: Advise and Consent. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007 , 21, 791-793		
68	Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 2-11	4.5	101
67	Inflammatory bowel disease: past, present, and future. <i>Journal of Gastroenterology</i> , 2007 , 42, 16-25	6.9	210
66	The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. <i>Gut</i> , 2007 , 56, 1387-92	19.2	55
65	The role of TNFalpha in ulcerative colitis. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 930-41	2.9	105
64	Selective leukocyte apheresis for the treatment of inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 874-88	3	27
63	Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?. <i>Gut</i> , 2006 , 55, 437-41	19.2	28
62	Possible association between isotretinoin and inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1569-73	0.7	104
61	Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2283-9	0.7	99
60	Risks and benefits of infliximab for the treatment of Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1017-24; quiz 976	6.9	115
59	New therapies for the treatment of inflammatory bowel disease. <i>Surgical Clinics of North America</i> , 2006 , 86, 1045-64	4	11
58	Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 587-91	3	2
57	GM-CSF. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, S12	4.5	

56	Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. <i>Journal of Clinical Gastroenterology</i> , 2006 , 40, 482-9	3	29
55	Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 47-56	2.6	24
54	Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1127-36	6.1	92
53	Review article: Medical therapy for fistulizing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1283-93	6.1	36
52	Risk factors for colorectal cancer in Crohn's colitis: a case-control study. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 491-6	4.5	41
51	Prevention and treatment of osteoporosis in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 797-813	4.5	62
50	Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. <i>Gastroenterology</i> , 2005 , 128, 862-9	13.3	485
49	Infliximab for induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2005 , 353, 2462-76	59.2	2906
48	A survey of methodological variation in the Crohn's disease activity index. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 133-8	4.5	37
47	Funding and Grantsmanship. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, S34-S37	4.5	1
46	Design issues and outcomes in IBD clinical trials. <i>Inflammatory Bowel Diseases</i> , 2005 , 11 Suppl 1, S22-8	4.5	28
45	State of the art: IBD therapy and clinical trials in IBD. <i>Inflammatory Bowel Diseases</i> , 2005 , 11 Suppl 1, S3-12	4.5	68
44	Infliximab maintenance therapy for fistulizing Crohn's disease. <i>New England Journal of Medicine</i> , 2004 , 350, 876-85	59.2	1727
43	Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. <i>Gut</i> , 2004 , 53, 1117-22	19.2	99
42	Risk factors for colon ischemia. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1333-7	0.7	82
41	Occurrence of colon ischemia in relation to irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2004 , 99, 486-91	0.7	102
40	Guidelines for immunizations in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2004 , 10, 677-92	4.5	175
39	Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 912-20	6.9	283

38	From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. <i>Gastroenterology</i> , 2004 , 126, 1518-32	13.3	256
37	Risk of early surgery for Crohn's disease: implications for early treatment strategies. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2712-8	0.7	106
36	Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1117-22	0.7	46
35	Effects of growth hormone secretion on body composition in patients with Crohn's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5468-72	5.6	25
34	Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 1355-64	6.1	76
33	Crohn's disease and IL-10 therapy: promise regained. <i>Inflammatory Bowel Diseases</i> , 2003 , 9, 210-1	4.5	5
32	O brother, where art thou? The case for siblings, environment, and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2003 , 9, 211-2	4.5	
31	A Crohn's Repertoire: T Cell Receptor α . <i>Inflammatory Bowel Diseases</i> , 2003 , 9, 213-214	4.5	
30	Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease \geq 100 points. <i>Gastroenterology</i> , 2003 , 124, A206	13.3	8
29	Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1882-6	5.9	36
28	Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 399-406	6.1	105
27	Collagenous Colitis: Budesonide Passes the Placebo Test. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 308	4.5	
26	Making Sense of Antisense Therapy for Murine Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 309-310	4.5	
25	The Sorcerer's Apprentice. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 310	4.5	
24	Perhaps we can, but should we?. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 372-3	4.5	
23	Irritable-inflammatory bowel disease: recognizing a new overlap syndrome and an enigma wrapped inside a puzzle. <i>Inflammatory Bowel Diseases</i> , 2002 , 8, 373-4	4.5	3
22	Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. <i>Inflammatory Bowel Diseases</i> , 2001 , 7, 83-8	4.5	305
21	Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 995-8	4	117

20	Therapy of inflammatory bowel disease. <i>Gastroenterology</i> , 2000 , 118, S68-82	13.3	176
19	New biologic agents: a critical appraisal. <i>Current Gastroenterology Reports</i> , 1999 , 1, 470-5	5	1
18	Infliximab for the treatment of fistulas in patients with Crohn's disease. <i>New England Journal of Medicine</i> , 1999 , 340, 1398-405	59.2	2286
17	New life in a sleeper: thalidomide and Crohn's disease. <i>Gastroenterology</i> , 1999 , 117, 1485-8	13.3	28
16	Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. <i>Gastroenterology</i> , 1999 , 117, 58-64	13.3	175
15	Novel therapies for inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 1999 , 28, 323-51	4.4	26
14	Treatment of ulcerative colitis. <i>Current Opinion in Gastroenterology</i> , 1999 , 15, 298-301	3	5
13	Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. <i>Gut</i> , 1998 , 43, 210-5	19.2	36
12	Biologic agents: data in adults and children. <i>Inflammatory Bowel Diseases</i> , 1998 , 4, 125-7; discussion 127-35	4.5	1
11	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-1997. A 58-year-old man with recurrent ulcerative colitis, bloody diarrhea, and abdominal distention. <i>New England Journal of Medicine</i> , 1997 , 337, 1532-40	59.2	3
10	Biologic Therapy for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 1997 , 3, 95-113	4.5	34
9	Biologic therapy for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 1997 , 3, 95-113	4.5	30
8	The trefoil peptide family. <i>Annual Review of Physiology</i> , 1996 , 58, 253-73	23.1	191
7	An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 5094-8	11.5	53
6	Molecular cloning of the rat intestinal trefoil factor gene. Characterization of an intestinal goblet cell-associated promoter. <i>Journal of Biological Chemistry</i> , 1995 , 270, 9353-61	5.4	28
5	Inflammatory bowel disease microbiotas alter gut CD4 T-cell homeostasis and drive colitis in mice		1
4	Gut microbiota density influences host physiology and is shaped by host and microbial factors		1
3	Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease		7

2	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium difficile Patients With and Without IBD	2
1	Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility	2